383 related articles for article (PubMed ID: 3023591)
21. Inhibition of converting enzyme in brain tissue and cerebrospinal fluid of rats following chronic oral treatment with the converting enzyme inhibitors ramipril and Hoe 288.
Gohlke P; Schölkens B; Henning R; Urbach H; Unger T
J Cardiovasc Pharmacol; 1989; 14 Suppl 4():S32-6. PubMed ID: 2483426
[TBL] [Abstract][Full Text] [Related]
22. Systemic and regional hemodynamic profile of five angiotensin I converting enzyme inhibitors in the spontaneously hypertensive rat.
Richer C; Doussau MP; Giudicelli JF
Am J Cardiol; 1987 Apr; 59(10):12D-17D. PubMed ID: 3034019
[TBL] [Abstract][Full Text] [Related]
23. Humoral and blood pressure effects of the angiotensin converting enzyme inhibitor ramipril in essential hypertension.
Lenz T; Distler A; Haller H; Meyer-Sabellek W; Wilp C; Tansey MJ; Eckert HG; Metzger H; Irmisch R; Philipp T
Arzneimittelforschung; 1986 Nov; 36(11):1693-6. PubMed ID: 3028438
[TBL] [Abstract][Full Text] [Related]
24. Reversal of the suppressed kidney renin level in the hypertensive transgenic rat TGR(mRen-2)27 by angiotensin converting enzyme inhibition.
Tokita Y; Franco-Saenz R; Mulrow PJ
Am J Hypertens; 1995 Oct; 8(10 Pt 1):1031-9. PubMed ID: 8845072
[TBL] [Abstract][Full Text] [Related]
25. [Tissue renin-angiotensin system. Physiology and physiopathological value of their inhibition by ramipril].
Clauser E
Rev Prat; 1990 Jun; 40(18 Suppl):10-5. PubMed ID: 2143594
[TBL] [Abstract][Full Text] [Related]
26. Renoprotective differences between perindopril and enalapril in the diabetic hypertensive rat do not reflect glomerular angiotensin-converting enzyme activity.
Duggan KA; Hodge G; Makarious MM; Charlesworth JA
Clin Sci (Lond); 1998 May; 94(5):511-6. PubMed ID: 9682674
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of action of enalapril in experimental hypertension and acute left ventricular failure.
Sweet CS; Gaul SL; Reitz PM; Blaine EH; Ribeiro LT
J Hypertens Suppl; 1983 Oct; 1(1):53-63. PubMed ID: 6100609
[TBL] [Abstract][Full Text] [Related]
28. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril.
Edling O; Bao G; Feelisch M; Unger T; Gohlke P
J Pharmacol Exp Ther; 1995 Nov; 275(2):854-63. PubMed ID: 7473177
[TBL] [Abstract][Full Text] [Related]
29. Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension.
Karlberg BE; Lindström T; Rosenqvist U; Ohman KP
Am J Cardiol; 1987 Apr; 59(10):104D-109D. PubMed ID: 3034016
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of a new angiotensin-converting enzyme inhibitor, ramipril, vs. enalapril in essential hypertension: a multicenter trial.
Mroczek WJ
J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S147-9. PubMed ID: 1725028
[TBL] [Abstract][Full Text] [Related]
31. The present molecules of converting enzyme inhibitors.
Brunner HR; Nussberger J; Waeber B
J Cardiovasc Pharmacol; 1985; 7 Suppl 1():S2-11. PubMed ID: 2580170
[TBL] [Abstract][Full Text] [Related]
32. [Interaction of chronic inhibition of the angiotensin-converting enzyme and the sympathetic system: effect of added sodium chloride load].
Dominiak P; Blöchl A
Z Kardiol; 1988; 77 Suppl 3():29-33. PubMed ID: 2905555
[No Abstract] [Full Text] [Related]
33. Long-term low-dose angiotensin converting enzyme inhibitor treatment increases vascular cyclic guanosine 3',5'-monophosphate.
Gohlke P; Lamberty V; Kuwer I; Bartenbach S; Schnell A; Linz W; Schölkens BA; Wiemer G; Unger T
Hypertension; 1993 Nov; 22(5):682-7. PubMed ID: 8225528
[TBL] [Abstract][Full Text] [Related]
34. Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure.
Squire IB; MacFayden RJ; Reid JL; Devlin A; Lees KR
J Cardiovasc Pharmacol; 1996 May; 27(5):657-66. PubMed ID: 8859935
[TBL] [Abstract][Full Text] [Related]
35. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).
Cushman DW; Wang FL; Fung WC; Grover GJ; Harvey CM; Scalese RJ; Mitch SL; DeForrest JM
Br J Clin Pharmacol; 1989; 28 Suppl 2(Suppl 2):115S-130S; discussion 130S-131S. PubMed ID: 2557876
[TBL] [Abstract][Full Text] [Related]
36. Physicochemical and enzyme binding kinetic properties of a new angiotensin-converting enzyme inhibitor ramipril and their clinical implications.
Bender N; Rangoonwala B; Rosenthal J; Vasmant D
Clin Physiol Biochem; 1990; 8 Suppl 1():44-52. PubMed ID: 2147879
[TBL] [Abstract][Full Text] [Related]
37. Prevention of stroke with perindopril treatment in stroke-prone spontaneously hypertensive rats.
Wang H; Delaney KH; Kwiecien JM; Smeda JS; Lee RM
Clin Invest Med; 1997 Oct; 20(5):327-38. PubMed ID: 9336658
[TBL] [Abstract][Full Text] [Related]
38. Biotransformation studies of di-acid angiotensin converting enzyme inhibitors.
Drummer OH; Kourtis S
Arzneimittelforschung; 1987 Nov; 37(11):1225-8. PubMed ID: 2964241
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological properties of the new orally active angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl] -(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
Becker RH; Schölkens BA; Metzger M; Schulze KJ
Arzneimittelforschung; 1984; 34(10B):1411-6. PubMed ID: 6097267
[TBL] [Abstract][Full Text] [Related]
40. Loop diuretics combined with an ACE inhibitor for treatment of hypertension: a study with furosemide, piretanide, and ramipril in spontaneously hypertensive rats.
Becker RH; Baldes L; Treudler M
J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S35-9. PubMed ID: 2474099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
